All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): YBL-013,Envafolimab
Therapeutic Area: Oncology Product Name: YBL-013
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: 3D Medicines
Deal Size: $87.0 million Upfront Cash: $2.0 million
Deal Type: Licensing Agreement January 05, 2021
Details:
3D Medicines will obtain rights to develop, manufacture, and commercialize YBL-013, a T cell bi-specific engager based on ALiCE platform technology, in the Territory of Greater China (mainland China, Hong Kong, Macau and Taiwan) and will co-developed it across the globe.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): LCB71
Therapeutic Area: Oncology Product Name: LCB71
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: CStone Pharmaceuticals
Deal Size: $353.5 million Upfront Cash: $10.0 million
Deal Type: Licensing Agreement October 29, 2020
Details:
CStone obtains the exclusive global right to lead development and commercialization of LCB71 outside the Republic of Korea. LCB71 is a pre-clinical ADC entering into Investigational New Drug (IND) enabling studies.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): AFM24,SNK01
Therapeutic Area: Oncology Product Name: AFM24
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Affimed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 20, 2020
Details:
Proof of Concept study to establish safety and recommended dose of Affimed’s innate cell engager (ICE®) AFM24 in combination with NKMax America’s Natural Killer (NK) cells in solid tumors.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BN-101A
Therapeutic Area: Oncology Product Name: BN-101A
Highest Development Status: Preclinical Product Type: Undisclosed
Partner/Sponsor/Collaborator: BioEleven
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership October 19, 2020
Details:
Under this agreement, Samsung Biologics will provide a full scope of its development services from cell line development, process development, to non-clinical and clinical material manufacturing as well as IND filing support.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ORIC-114
Therapeutic Area: Oncology Product Name: ORIC-114
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: ORIC Pharmaceuticals
Deal Size: $621.0 million Upfront Cash: $5.0 million
Deal Type: Licensing Agreement October 19, 2020
Details:
ORIC secured exclusive rights worldwide excluding the People’s Republic of China, Hong Kong, Macau and Taiwan (the ORIC Territory) for the development and commercialization of ORIC-114.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): STB-C017
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 15, 2020
Details:
Triple combination therapy of STB-C017, PD-1, CTLA-4 immune checkpoint inhibitors (ICIs) presented complete remission (CR) of tumor and long-term survival benefit.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): LCB73
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Iksuda
Deal Size: $227.0 million Upfront Cash: $5.0 million
Deal Type: Licensing Agreement May 15, 2020
Details:
LCB73 has been generated in a partnership between LCB and Swiss-based Light Chain Bioscience’s (Novimmune SA) by combining LCB’s cancer-selectively activated next-generation linker and toxin platform with Light Chain Bioscience’s proprietary antibody targeting CD19.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): GEN-001,Avelumab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 13, 2020
Details:
Clinical partnership of phase 1/1b combination clinical trial with Genome & Company's GEN-001, and avelumab, Merck KGaA, Darmstadt, Germany and Pfizer Inc.'s anti-PD-L1 antibody in cancer.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
